

Botulinum neurotoxin formulations: overcoming the confusion [Corrigendum]

Samizadeh S, De Boule K. *Clin Cosmet Invest Dermatol*. 2018;11:273–287.

On page 273, Introduction section, line 5, the sentence “The human nervous system is susceptible to BoNT-A, B, C, E, F, and G and unaffected by D.^{1,4-6}” should be changed to “The human nervous system is susceptible to BoNT-A, B, C, E, F, and G and almost unaffected by D.^{1,4-6,131}”.

On page 273, Introduction section, line 11, “BoNTs” should be changed to “botulinum toxins”.

On page 276, Table 2, Storage conditions column, “Below 8°C” should be changed to “2°C–8°C”.

On page 276, Table 2, Shelf life un-reconstituted column, “24 months” should be changed to “36 months”.

On page 276, right column, Composition section, line 12, “However, there is evidence that Hall strains are different to each other, and the strain information for the products apart from ONA (Allergan Botox[®]) is unknown.^{23–25}” should be changed to “However, there is evidence that Hall strains are different to each other and the strain information for ONA and INCO are known.^{23–25,30}”.

On page 282, Table 3 should be changed to:

Table 3 Correct definitions^{27,104}

Term	Definition
Spread	Physical movement An active and fast process
Diffusion	Kinetic spread A passive and slow process
Migration	The distal effects, for example via the “retrograde transport” phenomena

On page 282, Table 4 should be changed to:

Table 4 Immunogenicity vs primary nonresponse vs secondary nonresponse

Immunogenicity, and primary and secondary nonresponse	
Immunogenicity	Ability of a substance, eg, a protein to provoke an immune response and antibody formation
Primary nonresponse	Initial and following treatments fail to provoke a response
Secondary nonresponse	Initial treatment results in a response, no response with repeated administrations

Note: Data from Naumann et al.¹¹

On page 284, Disclosure section, “The authors report no conflicts of interest in this work.” should be changed to “Dr Koenraad De Boule has received honoraria, educational grants, acted as speaker or advisor for Allergan, Galderma, Merz and Revance. Dr Souphiyeh Samizadeh is the founder of the Great British of Aesthetic Medicine that organises scientific, non-biased, non-commercial and evidence based trainings, symposiums and congresses. The London 2017 Botulinum Toxin Pharmacology Symposium was organised by the Great British Academy of Aesthetic Medicine on the 29th of September 2017 at The Royal Society of Medicine. This was not a sponsored event and all invited speakers were asked to present a non-biased, scientific, evidence based talk. The authors report no other conflicts of interest in this work.”.

On page 287, the following reference should be added to the end of the reference list:

131. Eleopra R, Montecucco C, Devigili G, et al. Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study. *Clin Neurophysiol*. 2013;124(5):999–1004.